Saltar al contenido
Merck

Recent advances in PEG-PLA block copolymer nanoparticles.

International journal of nanomedicine (2010-12-21)
Ren Zhong Xiao, Zhao Wu Zeng, Guang Lin Zhou, Jun Jie Wang, Fan Zhu Li, An Ming Wang
RESUMEN

Due to their small particle size and large and modifiable surface, nanoparticles have unique advantages compared with other drug carriers. As a research focus in recent years, polyethylene glycol-polylactic acid (PEG-PLA) block copolymer and its end-group derivative nanoparticles can enhance the drug loading of hydrophobic drugs, reduce the burst effect, avoid being engulfed by phagocytes, increase the circulation time of drugs in blood, and improve bioavailability. Additionally, due to their smaller particle size and modified surface, these nanoparticles can accumulate in inflammation or target locations to enhance drug efficacy and reduce toxicity. Recent advances in PEG-PLA block copolymer nanoparticles, including the synthesis of PEG-PLA and the preparation of PEG-PLA nanoparticles, were introduced in this study, in particular the drug release and modifiable characteristics of PEG-PLA nanoparticles and their application in pharmaceutical preparations.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Poly(ethylene glycol) methyl ether-block-poly(D,L lactide), PEG average Mn 5000, PDLLA average Mn 20000
Sigma-Aldrich
N-Hydroxysuccinimide ester-poly(ethylene glycol)-b-poly(D,L lactide), PEG average Mn 5,000, PDLA average Mn 16,000
Sigma-Aldrich
Poly(ethylene glycol) methyl ether-block-poly(D,L lactide), PEG average Mn 5000, PDLA average Mn 50000
Sigma-Aldrich
Carboxylic acid-poly(ethylene glycol)-b-poly(D,L lactide), PEG average Mn 5,000, PDLA average Mn 55,000
Sigma-Aldrich
Carboxylic acid-poly(ethylene glycol)-b-poly(D,L lactide), PEG average Mn 5,000, PDLA average Mn 16,000